Shots:

• SK bioscience signs a development and supply agreement for Novavax’ NVX-CoV2373 to supply it globally including the COVAX facility. SK bioscience will manufacture the vaccine antigen component for use in the final drug product
• SK bioscience will utilize its cell culture and recombinant protein capability- will initiate the production of the NVX-CoV2373 antigen at its facility in Andong L-house- South Korea- expected to begin in Aug’2020
• Additionally- the companies have signed a letter of intent with the Republic of Korea’s Ministry of Health and Welfare for equitable access to NVX-CoV2373 in global market and to make it available in South Korea

­ Ref: PRNewswire | Image: Novavax